Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The prize was awarded to Harvey J. Alter, Michael Houghton and Charles M. Rice for their efforts to identify the virus. Prior to their work, the medical world was only aware of Hepatitis A and B.
Pfizer CEO Albert Bourla responds to COVID-19 being brought into this week’s presidential debate with political terms, rather than scientific facts.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
“We are very excited to have entered into this transformative agreement that marks the start of a new era for Vaccibody,” Michael Engsig, CEO of Vaccibody, said in a statement.
Merck announced that Roger M. Perlmutter, the company’s executive vice president and president of Merck Research Laboratories, was retiring effective January 1, 2021. He will be succeeded by Dean Y. Li.
At 74 years old, Trump is in a category of older Americans who are at more vulnerable to infection, and at higher risk of developing more serious symptoms.
The expansion is part of the company’s acquisition of a 500,000-square-foot property that Aphena will renovate “into a state-of-the-art pharmaceutical and packaging and distribution facility.”
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
As part of its half-year 2020 financial report, the company announced significant restructuring that will include cutting 40% of its staff.
Timothy Ray Brown, dubbed the “Berlin Patient,” the first ever to be cured of HIV, died from cancer on September 29.